TNF gene polymorphisms in cystic fibrosis patients: contribution to the disease progression

Journal of Translational Medicine

Vladimir Alioshkin⁵  Nikolai Kapranov³  Lucine Avakian³  Ekaterina Zakharova¹  Nika Petrova⁴  Alexander Pukhalsky³  Galina Shmarina² 

[1] Laboratory of Metabolic Diseases, Research Centre for Medical, Moscow, Russia;Laboratory of Cytokines, G. N. Gabrichevsky Institute of Epidemiology and Microbiology, Moscow, Russia;Department of Cystic Fibrosis, Research Centre for Medical Genetics, 1 Moskvorechie Street, Moscow, 115478, Russia;Laboratory of Genetic Epidemiology, Research Centre for Medical Genetics, Moscow, Russia;G. N. Gabrichevsky Institute of Epidemiology and Microbiology, Moscow, Russia

关键词: Asthma;    Tuberculosis;    Osteoporosis;    Liver disease;    Inflammation;    Cystic fibrosis;    Gene polymorphism;    TNF;   

Others  :  828195
DOI  :  10.1186/1479-5876-11-19

 received in 2012-11-20, accepted in 2013-01-18,  发布年份 2013

【 摘 要 】

Background

It is well known that the disease progression in cystic fibrosis (CF) patients may be diverse in subjects with identical mutation in CFTR gene. It is quite possible that such heterogeneity is associated with TNF-α and/or LT-α gene polymorphisms since their products play a key role in inflammation. The aim of the study was to investigate the possible roles of TNF gene polymorphisms in CF disease phenotype and progression.

Methods

198 CF patients and 130 control subjects were genotyped for both TNF-α–308GA and LT-α + 252AG polymorphisms.

Results

The carriers of the TNF-α–308A allele more frequently had asthma as compared to patients homozygous for the TNF-α–308 G allele. In 9 of 108 (8.3%) of LTα + 252AA carriers, tuberculosis infection has been documented, whereas there was no case of tuberculosis among patients, either homozygous or heterozygous for LTα +252 G alleles (p = 0.01). We never observed virus hepatitis among LTα + 252GA carriers. The genotypes TNF-α–308GG – LT-α + 252AA and TNF-α–308GA – LT-α + 252AG were unfavorable with regard to liver disease development (both p < 0.05). It was also shown that neutrophil elastase activity was higher in sputum specimens from high TNF producers with genotypes TNF-α–308GA or LT-α + 252GG. In addition the carriers of such genotypes demonstrated a higher risk of osteoporosis development (p values were 0.011 and 0.017, respectively).

Conclusions

The carriers of genotypes, which are associated with higher TNF-α production, demonstrated increased frequency of asthma, higher levels of neutrophil elastase, and decrease of bone density. On the contrary, the carriers of genotypes associated with low TNF-α production showed a higher frequency of tuberculosis infection.

【 授权许可】

   
2013 Shmarina et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Xie T, Rowen L, Aguado B, Ahearn ME, Madan A, Qin S, Campbell RD, Hood L: Analysis of the gene-dense major histocompatibility complex class III region and its comparison to mouse. Genome Res 2003, 13:2621-2636.
• [2]Campbell RD, Trowsdale J: Map of the human MHC. Immunol Today 1993, 14:349-352.
• [3]Bozzoni F, Beutler B: The tumor necrosis factor ligand and receptor families. N Engl J Med 1996, 334:1717-1725.
• [4]Locksley RM, Killeen N, Lenardo MJ: The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 2001, 104:487-501.
• [5]Elewaut D, Ware CF: The unconventional role of LT alpha beta in T cell differentiation. Trends Immunol 2007, 28:169-175.
• [6]Stanke F, Becker T, Kumar V, Hedtfeld S, Becker C, Cuppens H, Tamm S, Yarden J, Laabs U, Siebert B, Fernandez L, Macek M Jr, Radojkovic D, Ballmann M, Greipel J, Cassiman JJ, Wienker TF, Tümmler B: Genes that determine immunology and inflammation modify the basic defect of impaired ion conductance in cystic fibrosis epithelia. J Med Genet 2011, 48:24-31.
• [7]Vanscoy LL, Blackman SM, Collaco JM, Bowers A, Lai T, Naughton K, Algire M, McWilliams R, Beck S, Hoover-Fong J, Hamosh A, Cutler D, Cutting GR: Heritability of lung disease severity in cystic fibrosis. Am J Respir Crit Care Med 2007, 175:1036-1043.
• [8]Uglialoro AM, Turbay D, Pesavento PA, Delgado JC, McKenzie FE, Gribben JG, Hartl D, Yunis EJ, Goldfeld AE: Identification of three new single nucleotide polymorphisms in the human tumor necrosis factor-alpha gene promoter. Tissue Antigens 1998, 52:359-367.
• [9]Allen RD: Polymorphism of the human TNF-α promoter – random variation or functional diversity? Mol Immunol 1999, 36:1017-1027.
• [10]Messer G, Spengler U, Jung MC, Honold G, Blömer K, Pape GR, Riethmüller G, Weiss EH: Polymorphic structure of the tumor necrosis factor (TNF) locus: an NcoI polymorphism in the first intron of the human TNF-beta gene correlates with a variant amino acid in position 26 and a reduced level of TNF-beta production. J Exp Med 1991, 173:209-219.
• [11]Abraham LJ, French MA, Dawkins RL: Polymorphic MHC ancestral haplotypes affect the activity of tumour necrosis factor-alpha. Clin Exp Immunol 1993, 92:14-18.
• [12]Hull J, Thomson AH: Contribution of genetic factors other than CFTR to disease severity in cystic fibrosis. Thorax 1998, 53:1018-1021.
• [13]Yarden J, Radojkovic D, De Boeck K, Macek M Jr, Zemkova D, Vavrova V, Vlietinck R, Cassiman JJ, Cuppens H: Association of tumour necrosis factor alpha variants with the CF pulmonary phenotype. Thorax 2005, 60:320-325.
• [14]Zhang DL, Li JS, Jiang ZW, Yu BJ, Tang XM, Zheng HM: Association of two polymorphisms of tumor necrosis factor gene with acute biliary pancreatitis. World J Gastroenterol 2003, 9:824-828.
• [15]Stuber F, Petersen M, Bokelmann F, Schade U: A genomic polymorphism within the tumor necrosis factor locus influences plasma tumor necrosis factor-a concentrations and outcome of patients with severe sepsis. Crit Care Med 1996, 24:381-384.
• [16]Vissar L, Blout ER: The use of p-nitrophenyl N-tert-butyloxycarbonyl-L-alaninate as substrate for elastase. Biochim Biophys Acta 1972, 268:257-260.
• [17]Pukhalsky AL, Shmarina GV, Kapranov NI, Kokarovtseva SN, Pukhalskaya D, Kashirskaja NJ: Anti-inflammatory and immunomodulating effects of clarithromycin in patients with cystic fibrosis lung disease. Mediators Inflamm 2004, 13:111-117.
• [18]Bianchi ML: Osteoporosis in children and adolescents. Bone 2007, 41:486-495.
• [19]Zhang Y, Zhang J, Tian C, Xiao Y, He C, Li X, Bogati A, Huang J, Fan H: The −308 G/A polymorphism in TNF-α gene is associated with asthma risk: an update by meta- analysis. J Clin Immunol 2011, 31:174-185.
• [20]Masoli M, Fabian D, Holt S, Beasley R: The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy 2004, 59:469-478.
• [21]García-Elorriaga G, Carrillo-Montes G, Mendoza-Aguilar M, González-Bonilla C: Polymorphisms in tumor necrosis factor and lymphotoxin A in tuberculosis without and with response to treatment. Inflammation 2010, 33:267-275.
• [22]Efrati O, Barak A, Modan-Moses D, Augarten A, Vilozni D, Katznelson D, Szeinberg A, Yahav J, Bujanover Y: Liver cirrhosis and portal hypertension in cystic fibrosis. Eur J Gastroenterol Hepatol 2003, 15:1073-1078.
• [23]Agrons GA, Corse WR, Markowitz RI, Suarez ES, Perry DR: Gastrointestinal manifestations of cystic fibrosis: radiologic-pathologic correlation. RadioGraphics 1996, 16:871-893.
• [24]Colombo C, Battezzati PM, Crosignani A, Morabito A, Costantini D, Padoan R, Giunta A: Liver disease in cystic fibrosis: A prospective study on incidence, risk factors, and outcome. Hepatology 2002, 36:1374-1382.
• [25]Suneetha PV, Sarin SK, Goyal A, Kumar GT, Shukla DK, Hissar S: Association between vitamin D receptor, CCR5, TNF-α and TNF-β gene polymorphisms and HBV infection and severity of liver disease. J Hepatol 2006, 44:856-863.
• [26]Goyal A, Kazim SN, Sakhuja P, Malhotra V, Arora N, Sarin SK: Association of TNF-β polymorphism with disease severity among patients infected with hepatitis C virus. J Med Virol 2004, 72:60-65.
• [27]Bouma G, Xia B, Crusius JB, Bioque G, Koutroubakis I, Von Blomberg BM, Meuwissen SG, Peña AS: Distribution of four polymorphisms in the tumour necrosis factor (TNF) genes in patients with inflammatory bowel disease (IBD). Clin Exp Immunol 1996, 103:391-396.
• [28]Jiménez-Morales S, Velázquez-Cruz R, Ramírez-Bello J, Bonilla-González E, Romero-Hidalgo S, Escamilla-Guerrero G, Cuevas F, Espinosa-Rosales F, Martínez-Aguilar NE, Gómez-Vera J, Baca V, Orozco L: Tumor necrosis factor-alpha is a common genetic risk factor for asthma, juvenile rheumatoid arthritis, and systemic lupus erythematosus in a Mexican pediatric population. Hum Immunol 2009, 70:251-256.
• [29]Li YF, Gauderman WJ, Avol E, Dubeau L, Gilliland FD: Association of tumor necrosis factor G-308A with childhood asthma and wheezing. Am J Respir Crit Care Med 2006, 173:970-976.
• [30]Gordon MA, Oppenheim E, Camp NJ, di Giovine FS, Duff GW, Gleeson D: Primary biliary cirrhosis shows association with genetic polymorphism of tumour necrosis factor alpha promoter region. J Hepatol 1999, 31:242-247.
• [31]Wilson AG, Symons JA, McDowell TL, McDevitt HO, Duff GW: Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc Natl Acad Sci USA 1997, 94:3195-3199.
• [32]Corvol H, Beucher J, Boëlle PY, Busson PF, Muselet-Charlier C, Clement A, Ratjen F, Grasemann H, Laki J, Palmer CN, Elborn JS, Mehta A: Ancestral haplotype 8.1 and lung disease severity in European cystic fibrosis patients. J Cyst Fibros 2012, 11:63-67.